An Act To Protect The Health Of Medical Cannabis Patients And Streamline The Mandatory Testing Of Cannabis

Maine's LD 104 establishes a standardized testing program for medical cannabis to ensure patient safety before products reach consumers. The bill defines key terms like "batch," "matrix" (testing categories including flower, trim, and concentrates), and "remediation" (processes to fix contaminated batches without dilution). It requires testing facilities to be either licensed under state law or accredited to ISO/IEC 17025 standards, and mandates testing for contaminants and potency on all harvested cannabis before it can be sold or distributed to qualifying medical patients. This directly affects medical cannabis patients (by improving product safety), as well as caregivers, dispensaries, and manufacturers (who must comply with the new testing requirements).